ReAlta signs deal with NIAID to develop drug for radiation poisoning
US-based pharma company ReAlta Life Sciences has teamed up with the US National Institute of Allergy and Infectious Diseases (NIAID) to evaluate its acute radiation syndrome (ARS) drug RLS-0071 (PIC1-01). Scientists at the Armed Forces Radiobiology …